FDA Asks Pfizer For More Data On Anti-Smoking Drug

Law360, New York (November 21, 2007, 12:00 AM EST) -- The U.S Food and Drug Administration said it had received reports of suicidal thoughts and erratic behavior in smokers taking Pfizer Inc's anti-smoking drug Chantix and has asked the pharmaceutical giant to produce more post-marketing data on the medication.

The agency, which is currently evaluating adverse event reports for Chantix, said Tuesday it had not made any definitive conclusions about the safety of the prescription drug and wanted more information before completing its review.

A Pfizer spokesperson did not return calls for comment Wednesday, but the...
To view the full article, register now.